{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:50:56Z","timestamp":1791640256882,"version":"4.3.4"},"reference-count":35,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Blood &amp;amp; Cancer"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Graft\u2010versus\u2010host disease (GvHD) remains one of the most significant complications of hematopoietic stem cell transplantation (HSCT). Abatacept, a selective T\u2010cell costimulation modulator, is a relatively novel prophylactic agent, though pediatric data remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Procedure<\/jats:title>\n                    <jats:p>A systematic review and meta\u2010analysis was conducted to evaluate the efficacy and safety of abatacept for GvHD prophylaxis in pediatric HSCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifteen cohort studies were identified (eight comparative and seven single\u2010arm). Studies included abatacept as adjunctive agent to traditional regimens. Pooled analyses demonstrated that abatacept\u2010inclusive regimens significantly reduced the risk of Grade II\u2013IV acute GvHD (aGvHD) (risk ratio [RR] 0.31, 95% confidence interval [CI] 0.14\u20130.65) and severe Grade III\u2013IV aGvHD (RR 0.14, 95% CI 0.05\u20130.37). Abatacept administration was not associated with decreased moderate\u2010to\u2010severe chronic GvHD incidence, although extended regimens were associated with reduced risk (RR 0.25, 95% CI 0.08\u20130.78). Abatacept\u2010inclusive GvHD prophylaxis was not associated with compromised immune reconstitution or increased viral reactivations, whereas it was associated with a reduced incidence of bacterial infections (RR 0.39, 95% CI 0.21\u20130.74) and improved overall survival (RR 1.18, 95% CI 1.03\u20131.34).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite limitations inherent to retrospective study designs and cohort heterogeneity, these findings indicate that abatacept is an efficacious and safe addition to GvHD prophylaxis in pediatric HSCT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/1545-5017.70746","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:00:16Z","timestamp":1791637216000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Abatacept for Prophylaxis of Acute and Chronic Graft\u2010Versus\u2010Host\u2010Disease in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation\u2014A Systematic Review and Meta\u2010Analysis of Cohort Studies"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2054-2187","authenticated-orcid":false,"given":"Matthijs D.","family":"Kruizinga","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Pediatric Stem Cell Transplantation Program, Willem\u2010Alexander Children's Hospital Leiden University Medical Center  Leiden the Netherlands"},{"name":"Juliana Children's Hospital Haga Teaching Hospital  The Hague the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4801-0403","authenticated-orcid":false,"given":"Anne B.","family":"Verbeek","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Pediatric Stem Cell Transplantation Program, Willem\u2010Alexander Children's Hospital Leiden University Medical Center  Leiden the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3984-5620","authenticated-orcid":false,"given":"Caroline A.","family":"Lindemans","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology  Utrecht the Netherlands"},{"name":"Department of Pediatrics Wilhelmina Children's Hospital UMC Utrecht Utrecht University  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2755-9408","authenticated-orcid":false,"given":"Emilie P.","family":"Buddingh","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Pediatric Stem Cell Transplantation Program, Willem\u2010Alexander Children's Hospital Leiden University Medical Center  Leiden the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,10]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(19)30158\u20109"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.06.008"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.11.004"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2215943"},{"key":"e_1_2_10_6_1","volume-title":"The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies","author":"Boelens J. J.","year":"2024"},{"key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2017-05-780239","article-title":"Phase 1 Clinical Trial Evaluating Abatacept in Patients With Steroid\u2010Refractory Chronic Graft\u2010Versus\u2010Host Disease","volume":"131","author":"Nahas M. R.","year":"2018","journal-title":"Blood"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.09.003"},{"key":"e_1_2_10_9_1","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1200\/JCO.20.01086","article-title":"Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD","volume":"39","author":"Watkins B.","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/publications14010004"},{"key":"e_1_2_10_12_1","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2019"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2017.07.004"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409\u2010023\u201002034\u2010z"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008545"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.12.010"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409\u2010025\u201002601\u20106"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025017197"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.32085"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.06.015"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.03.010"},{"issue":"16","key":"e_1_2_10_22_1","first-page":"3894","article-title":"Abatacept Is Effective as GVHD Prophylaxis in Unrelated Donor Stem Cell Transplantation for Children With Severe Sickle Cell Disease","volume":"4","author":"Ngwube A.","year":"2020","journal-title":"Blood Advances"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.12.016"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409\u2010025\u201002566\u20106"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010208717"},{"key":"e_1_2_10_26_1","doi-asserted-by":"crossref","unstructured":"F.Quagliarella M.Algeri E.Boccieri P.Merli andF.Locatelli B009\u2014Abatacept Reduces Acute GVHD Incidence and Improves GRFS in Pediatric Patients Transplanted From an HLA\u2010Mismatched Donor: A Real\u2010World Multicenter Retrospective Study(EBMT 2026).","DOI":"10.1016\/j.jtct.2026.10.009"},{"key":"e_1_2_10_27_1","unstructured":"U.Kapoor E. O.Stenger M. D.Qayed et\u00a0al. \u201cAbatacept for GVHD Prophylaxis in Pediatric Severe Aplastic Anemia Undergoing Unrelated Donor Hematopoietic Cell Transplant: A Single\u2010Center Experience \u201d inAbstracts from the 2026 Tandem Meetings of ASTCT and CIBMTR Salt Lake City Utah USA February 4\u20137 2026."},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.12.866"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.09.025"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207231152644"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1320692"},{"issue":"17","key":"e_1_2_10_32_1","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood.2023023660","article-title":"Abatacept for Acute Graft\u2010Versus\u2010Host Disease Prophylaxis After Unrelated Donor Hematopoietic Cell Transplantation","volume":"144","author":"Kean L. S.","year":"2024","journal-title":"Blood"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020035"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.70156"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000002705"},{"key":"e_1_2_10_36_1","unstructured":"CHMP Withdrawal Assessment Report\u2014Orencia Procedure No. EMEA\/H\/C\/000701\/0152(CHMP 2024) https:\/\/www.ema.europa.eu\/en\/medicines\/human\/variation\/orencia."}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/1545-5017.70746","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/1545-5017.70746","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/1545-5017.70746","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:00:23Z","timestamp":1791637223000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/1545-5017.70746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,10]]},"references-count":35,"alternative-id":["10.1002\/1545-5017.70746"],"URL":"https:\/\/doi.org\/10.1002\/1545-5017.70746","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,10]]},"assertion":[{"value":"2026-07-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70746"}}